Form 4: Kymera Director Esposito Exercises, Sells Shares

Kymera Therapeutics Director Pamela Esposito exercised stock options and simultaneously sold 5,500 shares of common stock on January 20, 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Pamela Esposito, a Director at Kymera Therapeutics, Inc. (KYMR), engaged in transactions on January 20, 2026.
• She exercised stock options to acquire 3,000 shares of common stock at an exercise price of $31.2 per share.
• She also exercised stock options to acquire an additional 2,500 shares of common stock at an exercise price of $49.1 per share.
• Concurrently, she sold a total of 5,500 shares of common stock.
• The sales included 400 shares at a weighted average price of $66.68, 4,900 shares at a weighted average price of $67.9888, and 200 shares at $68.52.
• All transactions were conducted under a Rule 10b5-1 trading plan established on September 17, 2025.
• Following these transactions, Pamela Esposito holds 0 shares of common stock directly, but retains 10,000 stock options exercisable at $31.2 and 5,000 stock options exercisable at $49.1.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling all directly held common stock, even though the transactions were pre-planned under a 10b5-1 plan and options remain. While not a strong negative signal due to the 10b5-1 plan, it still represents a reduction in direct insider equity exposure.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were not based on new, non-public information.
• The director exercised options, realizing value from previously granted equity.

Negatives

• A director sold a significant number of shares (5,500 shares), reducing their direct common stock ownership to zero.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to minor negative sentiment, although the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

While the director sold all directly held common stock, the transactions were executed under a pre-established 10b5-1 trading plan, which suggests the sales were for personal financial planning rather than based on new, material non-public information. The director still retains significant stock options. Therefore, this filing alone does not warrant a 'sell' recommendation, but the reduction in direct equity exposure prevents a 'buy' recommendation. A 'hold' stance is appropriate, awaiting further company-specific news or broader market trends.

Keywords

Kymera Therapeutics, KYMR, Pamela Esposito, Insider Trading, Form 4, Stock Options, Share Sale, Director Transactions, 10b5-1 Plan